Acumen pharmaceuticals to participate in the bank of america cns therapeutics virtual conference

Newton, mass., sept. 30, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the bank of america cns therapeutics virtual conference on monday, oct. 7, 2024, at 8:00 a.m. et.
ABOS Ratings Summary
ABOS Quant Ranking